SUCCESSOR-1: A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Condition: Multiple Myeloma
Sponsor: Celgene Corporation
Full Title
Protocol CA057-001: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
Study Treatment
1:1 randomization between the following treatment arms:
Arm A: Mezigdomide (modulator of the E3 ubiquitin ligase complex containing cereblon) in combination with Bortezomib and Dexamethasone
Arm B: Pomalidomide, Bortezomib, and Dexamethasone
Eligibility/Info
Relapsed or refractory multiple myeloma that has continued to grow or that has come back after 1-3 prior lines of antimyeloma systemic therapy that included lenalidomide.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
